KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Assets (2017 - 2025)

Novartis Ag (NVS) has disclosed Assets for 9 consecutive years, with $110.9 billion as the latest value for Q4 2025.

  • Quarterly Assets rose 8.51% to $110.9 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $110.9 billion through Dec 2025, up 8.51% year-over-year, with the annual reading at $110.9 billion for FY2025, 8.51% up from the prior year.
  • Assets hit $110.9 billion in Q4 2025 for Novartis Ag, up from $102.2 billion in the prior quarter.
  • In the past five years, Assets ranged from a high of $131.8 billion in Q4 2021 to a low of $99.9 billion in Q4 2023.
  • Historically, Assets has averaged $112.5 billion across 5 years, with a median of $110.9 billion in 2025.
  • Biggest five-year swings in Assets: decreased 14.91% in 2023 and later rose 8.51% in 2025.
  • Year by year, Assets stood at $131.8 billion in 2021, then dropped by 10.88% to $117.5 billion in 2022, then dropped by 14.91% to $99.9 billion in 2023, then grew by 2.3% to $102.2 billion in 2024, then increased by 8.51% to $110.9 billion in 2025.
  • Business Quant data shows Assets for NVS at $110.9 billion in Q4 2025, $102.2 billion in Q4 2024, and $99.9 billion in Q4 2023.